Business Context and Reporting Period
This Form 8-K Current Report, dated June 30, 2021, covers Philip Morris International Inc. (PMI) and its wholly owned subsidiary, PMI Global Services, Inc. The filing reports the entry into a Material Definitive Agreement on June 30, 2021, regarding the acquisition of Fertin Pharma A/S, a developer and manufacturer of pharmaceuticals and nutraceutical products based on oral and intra-oral delivery systems.
Key Financial Metrics and Transaction Details
The filing details a proposed acquisition rather than reporting standard quarterly financial metrics such as revenue or profit. Key transaction financials include:
- Enterprise Value: DKK 5,121,500,000 (approximately USD 820 million).
- Valuation Basis: Adjusted for consolidated net interest-bearing debt and normalized working capital as of the Locked Box Date (March 31, 2021).
- Interest Accrual: The Base Purchase Price accrues interest at 2.5% per annum from the Locked Box Date through the closing date.
- Currency Conversion: Based on the average conversion rate on June 29, 2021 (DKK 1.00 = USD).
The filing text does not provide clear values for PMI's current revenue, profit, cash flow, margins, or overall debt levels outside the context of this specific transaction.
Material Changes and Transaction Structure
PMI has entered into a Share Sale and Purchase Agreement to acquire all issued and outstanding shares of Claudio Holdco A/S, the ultimate holding company of Fertin. The transaction involves:
- Sellers: Claudio Topco B.V. and Bagger-Sorensen & Co. A/S (Majority Sellers), along with certain minority sellers via a drag-along process.
- Restrictions: Sellers are subject to non-compete restrictions for two years and non-solicitation provisions for key employees for three years (reduced to six months for salaried employees under Danish law).
- Indemnification: Claims for breaches of warranties are to be made exclusively under a warranty and indemnity insurance policy, except in cases of fraud, willful misconduct, or uncovered fundamental warranty breaches.
Guidance, Outlook, and Risks
Closing Conditions and Timeline:
- The transaction is subject to customary closing conditions, including antitrust and governmental approvals.
- Expected Closing: On or around October 6, 2021.
- Termination Date: The agreement may be terminated if closing does not occur by December 30, 2021, subject to a potential six-month extension if approvals are pending.
Risks and Contingencies:
- The consummation of the transaction is not guaranteed and depends on regulatory approvals.
- Representations and warranties in the agreement are subject to qualifications, limitations, and confidential disclosures, and may not reflect facts applicable to investors.
Important Facts for Investor Verification
- Verify the status of required antitrust and governmental approvals for the Fertin acquisition.
- Confirm the final closing date, as the current target is October 6, 2021, with a potential extension.
- Review the final purchase price adjustment based on net debt and working capital as of the March 31, 2021 Locked Box Date.
- Monitor the integration strategy for Fertin's oral and intra-oral delivery systems into PMI's existing portfolio.